NASAL SPRAY FOR MIGRAINE PAIN RELIEF
Researchers are
developing a novel prochlorperazine nasal spray formulation as a potential new
treatment for migraines. This work is being presented at the 2014 American
Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition
in San Diego, Nov. 2-6.
Migraines are
manifested by severe pain and headache that can last anywhere from four to
seventy-two hours, accompanied by nausea, vomiting, and sensitivity to both
light and sound. Of the 100 million people that experience headaches in the
United States, 37 million of them suffer from migraines. According to the
Migraine Research Foundation, migraine ranks in the top 20 of the world's most
disabling medical diseases, with someone in the United States going to the
emergency room every 10 seconds for treatment.
Venkata Yellepeddi,
Ph.D., along with his colleagues from Roseman University of Health Sciences, developed
a preservative-free device-driven prochlorperazine nasal spray that could prove
useful for compounding pharmacists specifically in the field of pain medicine.
"Prochloperazine is a dopamine receptor antagonist that is widely used as
an anti-nausea medication. Comparative clinical studies have shown that
prochloperazine provides better pain relief than other anti-migraine drugs such
as sumatriptan, metoclopramide, and ketorolac," said Yellepeddi.
"Currently, there are no marketed nasal spray formulations of
prochlorperazine available for the treatment of migraine. Prochlorperazine is
only available in tablet form, which has delayed onset of action."
Yellepeddi and his team hypothesize that a nasal spray version of
prochlorperazine will not only be effective, but fast acting and have better
patient compliance overall. Furthermore, this novel product does not have any
preservative-related adverse side effects, such as mucosal irritation which are
normally seen with vehicles with preservatives such as benzalkonium chloride
and potassium sorbate.
Yellepeddi used high
performance liquid chromatography and microbiological assays to assess the
stability of prochloperazine nasal spray. These studies demonstrated that the
nasal spray was able to remain stable for up to 120 days with minimal
degradation, therefore making it an effective treatment option for migraine
patients.
The next stage of
Yellepeddi's research is to test the safety, efficacy, and pharmacokinetic
studies of the prochlorperazine nasal spray in rat animal models.
Comments
Post a Comment